undamentalytics Newsletter
Sign in

Vaxcyte, Inc. (PCVX) stock

Add to watchlist

Add holding +

NASDAQ: PCVX Nasdaq Biotechnology Next results ~November 3, 2026

Vaxcyte, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Vaxcyte, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 3 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 55% and a beta of 1.1 against the S&P 500.
  • Insiders selling. 5 insiders sold $12M of stock over the past 365 days and none bought (92% under pre-set trading plans).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results

Earnings per share
-$1.97 against an average estimate of -$2.10: beat by 6.1%
Share reaction
+7.7% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 3, 2026; average EPS estimate -$2.11

Vaxcyte's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.3%
  • 1 week+1.1%
  • 1 month+7.3%
  • This year+31.4%
  • 1 year+33.9%
  • 5 years+142.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 5, 2026
Next results (est.)
November 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Announcement
  3. Insider trade
  4. Insider trade
  5. Leadership
  6. Results
  7. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Vaxcyte, Inc. valuation models and calculator

No model value for Vaxcyte, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $0 and EPS of −$2.11 (range −$2.68 to −$1.67) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$8.14 −45% — 0%
Next −$7.12 +13% $87m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −4.0% on 90 days ago. In the last 30 days, 0 analysts raised Vaxcyte, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Vaxcyte, Inc., last 90 days
−$10.00 −$5.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$8.48 Current fiscal year, 60 days ago: −$8.20 Current fiscal year, 30 days ago: −$8.20 Current fiscal year, 7 days ago: −$8.23 Current fiscal year, Now: −$8.14 −$8.14 Next fiscal year, 90 days ago: −$7.42 Next fiscal year, 60 days ago: −$7.22 Next fiscal year, 30 days ago: −$7.22 Next fiscal year, 7 days ago: −$7.19 Next fiscal year, Now: −$7.12 −$7.12

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$8.48−$7.42
60 days ago −$8.20−$7.22
30 days ago −$8.20−$7.22
7 days ago −$8.23−$7.19
Now −$8.14−$7.12

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$2.10 −$1.97 +6.1%
Mar 2026 −$1.77 −$2.30 −29.6%
Dec 2025 −$1.50 −$1.80 −19.7%
Sept 2025 −$1.24 −$1.56 −26.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

11 analysts, Oct 2026
Buy1091%
Hold19%
Sell00%

Monthly trend

  1. Oct 202619111
  2. Sep 202619111
  3. Aug 202619111
  4. Jul 202619111

Counts of recommendations published by analysts covering Vaxcyte, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
9.3%
of tradable shares
Days to cover
4.4
at average volume
Short interest, 1 month
−9%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.5%
of shares
Employees
507
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PCVX−11%+102%+31%+30%−44%+31%
Industry peers (median)−36%−57%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PCVX33%67%50%58%50%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PCVX−44%−34%−28%−31%−70%−28%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since June 12, 2020: 76% from October 16, 2024 to April 10, 2025. Getting back needed a 321% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$40.32 – $73.82
From 52-week high
−17.9%
vs 50-day average
−1.5%
vs 200-day average
+6.2%
Volatility (1 year)
55%
Beta vs S&P 500
1.11

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±5.2%
After a week
5 up, 7 down
typical move ±6.1%
After a month
6 up, 6 down
typical move ±15.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 +7.7% −0.4% +9.1% +11.8%
May 6, 2026 −7.5% +1.1% −2.5% −14.9%
February 24, 2026 +4.6% +1.6% −0.7% −7.2%
November 4, 2025 −5.9% −0.8% +6.6% +7.6%
August 6, 2025 −11.0% +0.7% −6.5% −2.1%
May 7, 2025 +7.6% +1.1% +0.6% +26.5%
February 25, 2025 −3.7% −0.4% −14.0% −16.1%
November 5, 2024 −2.3% +3.7% −6.7% −15.4%
August 6, 2024 −3.1% +0.2% +6.2% +54.1%
May 8, 2024 −2.9% +0.6% +6.1% +5.1%
February 27, 2024 −4.9% +0.1% −9.5% −13.3%
November 6, 2023 −1.0% +0.5% −4.6% +10.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$9.7B
Institutions reporting
327
Shares held vs prior quarter
▲ 2.9%
Positions opened / closed
42 / 50

Top buyers and sellers, Q2 2026: 174 institutions bought and 150 sold ; the biggest buyer was FMR LLC (+4.4M shares) and the biggest seller Paradigm Biocapital Advisors LP (−2.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $1.2B 20.9M 12.5% ▲ 26.4%
Jupiter Topco LLC $1B 18.0M 10.7% —
T. Rowe Price Investment Management, Inc. $710M 12.2M 7.3% ▲ 0.7%
Blackrock, Inc. $702M 12.1M 7.2% ▲ 10.0%
RA Capital Management, L.P. $667M 11.5M 6.9% 0.0%
Wellington Management Group LLP $407M 7.0M 4.2% ▲ 24.7%
Vanguard Portfolio Management LLC $383M 6.6M 3.9% ▲ 5.0%
Vanguard Capital Management LLC $369M 6.3M 3.8% ▲ 1.3%
State Street Corp $311M 5.4M 3.2% ▲ 20.5%
Deep Track Capital, LP $250M 4.3M 2.6% 0.0%
Geode Capital Management, LLC $201M 3.5M 2.1% ▲ 8.1%
Price T Rowe Associates Inc $174M 3.0M 1.8% ▲ 206.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Vaxcyte, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $12.4M 53 trades by 5 insiders · 92% under pre-set plans
Net ▼ $12.4M net selling
Insider Date Trade Shares Price Value
Cowan Elvia SVP, Finance & CAO October 5, 2026 Sell pre-set plan 19,000 $86.74 $1.6M
Wassil Jim EVP, Chief Scientific Ofc, COO October 5, 2026 Sell pre-set plan 18,000 $86.74 $1.6M
Wassil Jim EVP, Chief Scientific Ofc, COO October 1, 2026 Sell pre-set plan 95 $57.09 $5,424
Wassil Jim EVP, Chief Scientific Ofc, COO October 1, 2026 Sell pre-set plan 2,155 $56.65 $122,089
Wassil Jim EVP, Chief Scientific Ofc, COO September 9, 2026 Sell pre-set plan 1,334 $59.52 $79,400
Wassil Jim EVP, Chief Scientific Ofc, COO September 4, 2026 Sell pre-set plan 1,381 $61.16 $84,462
Wassil Jim CHIEF OPERATING OFFICER September 1, 2026 Sell pre-set plan 924 $60.96 $56,327
Wassil Jim CHIEF OPERATING OFFICER September 1, 2026 Sell pre-set plan 713 $61.48 $43,835
Wassil Jim CHIEF OPERATING OFFICER September 1, 2026 Sell pre-set plan 1,537 $60.89 $93,588
Wassil Jim CHIEF OPERATING OFFICER September 1, 2026 Sell pre-set plan 303 $61.42 $18,610
Dhaliwal Harpreet S. Chief Technical Ops Officer August 5, 2026 Sell pre-set plan 17,000 $55.00 $935,000
Guggenhime Andrew PRESIDENT AND CFO August 3, 2026 Sell pre-set plan 3,044 $54.18 $164,924

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 9 trades and filings

In the last 12 months, 1 member of Congress disclosed 3 purchases and 0 sales of Vaxcyte, Inc. shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded July 16, 2026, filed September 4, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded May 13, 2026, filed June 8, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded May 12, 2026, filed June 8, 2026

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 3, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 6, 2026
  • February 24, 2026
  • November 4, 2025
  • August 6, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Vaxcyte, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Vaxcyte, Inc. in brief

What does Vaxcyte, Inc. do?
Vaxcyte, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Vaxcyte, Inc.'s stock ticker?
Vaxcyte, Inc. trades under the ticker PCVX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Vaxcyte, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Jupiter Topco LLC and T. Rowe Price Investment Management, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Vaxcyte, Inc. stock?
Over the last 12 months, Vaxcyte, Inc.'s directors and officers reported 0 open-market purchases and 53 sales on Form 4. The insider trading page charts every trade.
When is Vaxcyte, Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Vaxcyte, Inc. announces its own schedule.